Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rintatolimod by AIM ImmunoTech for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Rintatolimod by AIM ImmunoTech for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS)....
Rintatolimod by AIM ImmunoTech for Melanoma: Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Melanoma. According to GlobalData, Phase II...